Table 4.
Summary of previous studies for the investigation of the efficacy of second-line eradication therapy for H. pylori infection.
| First author [ref. no.] | Year | Method | VPZ-containing eradication regimen |
PPI-containing eradication therapy |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Number | Regimen | Eradication rate | Number | Regimen | Eradication rate | ||||
| Murakami (Murakami et al., 2016) | 2016 | RCT | PP | 50 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
98.0 | |||
| Inaba (Inaba et al., 2016) | 2016 | RST | ITT | 37 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 mg bid |
70.2%∗ | |||
| Yamada (Yamada et al., 2016) | 2016 | RST | ITT | 66 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
89.6% | 386 | LPZ: 30 mg bid, RPZ: 10 mg bid, EPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
89.9% |
| Tsujimae (Tsujimae et al., 2016) | 2016 | RST | ITT | 46 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
89.1% | 54 | EPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
83.3% |
| Katayama (Katayama et al., 2017) | 2017 | RST | ITT | 24 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
87.0% | |||
| Ono (Ono et al., 2017) | 2017 | RST | ITT | 1 | VPZ: 20 mg bid MNZ: 250 mg bid CLR: 200 mg bid |
100% | 3 | LPZ: 30 mg bid or RPZ: 10 mg bid MNZ: 250 mg bid CLR: 200 mg bid |
33.3% |
| 3 | VPZ: 20 mg bid MNZ: 250 mg bid STFX: 100 mg bid |
66.7% | 24 | LPZ: 30 mg bid or RPZ: 10 mg bid MNZ: 250 mg bid STFX: 100 mg bid |
100% | ||||
| Sakurai (Sakurai et al., 2017) | 2017 | RST | ITT | 76 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
96.1% | 185 | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
89.7% |
| Sugimoto (Sugimoto et al., 2017) | 2017 | OS | ITT | 29 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
93.1% | |||
| Sue (Sue et al., 2017a) | 2017 | RST | ITT | 216 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
80.5% | 146 | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
81.5% |
| Nishizawa (Nishizawa et al., 2017) | 2017 | RST | ITT | 85 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
71.8% | 650 | LPZ: 30 mg bid or RPZ: 10 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
73.7% |
| Tanabe (Tanabe et al., 2017) | 2017 | OS | ITT | 73 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
90.4% | |||
| Ozaki (Ozaki et al., 2018) | 2018 | RST | ITT | 94 | VPZ: 20 mg bid AMX: 750 mg bid MNZ: 250 mg bid |
86.3% | |||
All paper to investigate efficacy of second-line vonoprazan-containing eradication therapy up until September 2018 were listed. AMX, amoxicillin; bid, twice daily dosing; CLR, clarithromycin; EPZ, esomeprazole; ITT, intention to treat analysis; LPZ, lansoprazole; MNZ, metronidazole; OPZ, omeprazole; PP, per protocol analysis; PPI, proton pump inhibitor; OS, observational study; RCT, randomized control trial; RST, retrospective cohort trial; RPZ, rabeprazole; VPZ, vonoprazan.